Literature DB >> 12096932

Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention?

Hideki Matsuoka1, Rikuzo Hamada.   

Abstract

Intracerebral haemorrhage (ICH) results in high mortality and morbidity. The most important causes of neurological deterioration after ICH are progression of oedema and injury to nerve cells and axons surrounding the haematoma, as well as haematoma enlargement. Recent studies have indicated that thrombin, formed upon clotting of the haematoma, plays an important role in these processes. As opposed to conventional therapeutic approaches, administration of a thrombin inhibitor could effectively limit oedema formation and neuronal damage, improving survival and functional outcome. A small, preliminary clinical trial has suggested that antithrombin therapy with intravenously administered argatroban may be useful in treatment of ICH. Randomised, controlled studies are needed to confirm these initial findings.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096932     DOI: 10.2165/00023210-200216080-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  77 in total

Review 1.  Clinical trials of recombinant hirudin in acute coronary syndromes.

Authors:  R Challapalli; J Lefkovits; E J Topol
Journal:  Coron Artery Dis       Date:  1996-06       Impact factor: 1.439

2.  Pharmacology of argatroban.

Authors:  W Jeske; J M Walenga; B E Lewis; J Fareed
Journal:  Expert Opin Investig Drugs       Date:  1999-05       Impact factor: 6.206

3.  [Treatment of cerebral infarction in the acute stage with synthetic antithrombin MD-805: a multicenter clinical study].

Authors:  Y Yonekawa; H Handa; S Okamoto; Y Kamijo; Y Oda; J Ishikawa; H Tsuda; Y Shimizu; M Satoh; T Yamagami
Journal:  Nihon Geka Hokan       Date:  1986-09-01

4.  Management of intracranial hemorrhage associated with anticoagulant therapy.

Authors:  T Kawamata; M Takeshita; O Kubo; M Izawa; M Kagawa; K Takakura
Journal:  Surg Neurol       Date:  1995-11

5.  Vasodilatation in the canine leg caused by intraarterial infusion of thrombin and tissue thromboplastin.

Authors:  A Delin; P Olsson; A C Teger-Nilsson
Journal:  Cardiovasc Res       Date:  1967-10       Impact factor: 10.787

6.  Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain.

Authors:  H Ishii; H H Salem; C E Bell; E A Laposata; P W Majerus
Journal:  Blood       Date:  1986-02       Impact factor: 22.113

7.  Plasminogen activators potentiate thrombin-induced brain injury.

Authors:  B E Figueroa; R F Keep; A L Betz; J T Hoff
Journal:  Stroke       Date:  1998-06       Impact factor: 7.914

8.  Effects of experimental intracerebral hemorrhage on blood flow, capillary permeability, and histochemistry.

Authors:  F P Nath; P T Kelly; A Jenkins; A D Mendelow; D I Graham; G M Teasdale
Journal:  J Neurosurg       Date:  1987-04       Impact factor: 5.115

9.  Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.

Authors:  C N Berry; C Girardot; C Lecoffre; C Lunven
Journal:  Thromb Haemost       Date:  1994-09       Impact factor: 5.249

10.  Cerebral arterial contractions induced by human and bovine thrombin.

Authors:  R P White; C E Chapleau; M Dugdale; J T Robertson
Journal:  Stroke       Date:  1980 Jul-Aug       Impact factor: 7.914

View more
  12 in total

Review 1.  Update on intracerebral haemorrhage.

Authors:  José M Ferro
Journal:  J Neurol       Date:  2006-05-06       Impact factor: 4.849

2.  Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage.

Authors:  G Li; R-M Fan; J-L Chen; C-M Wang; Y-C Zeng; C Han; S Jiao; X-P Xia; W Chen; S-T Yao
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

3.  PDGFR-α inhibition preserves blood-brain barrier after intracerebral hemorrhage.

Authors:  Qingyi Ma; Bin Huang; Nikan Khatibi; William Rolland; Hidenori Suzuki; John H Zhang; Jiping Tang
Journal:  Ann Neurol       Date:  2011-12       Impact factor: 10.422

4.  Aquaporin and vascular diseases.

Authors:  Carla Loreto; Ester Reggio
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

Review 5.  Role of aquaporin-4 in cerebral edema and stroke.

Authors:  Zsolt Zador; Shirley Stiver; Vincent Wang; Geoffrey T Manley
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Protease-activated receptor 1-dependent neuronal damage involves NMDA receptor function.

Authors:  Cecily E Hamill; Guido Mannaioni; Polina Lyuboslavsky; Aristide A Sastre; Stephen F Traynelis
Journal:  Exp Neurol       Date:  2009-02-10       Impact factor: 5.330

7.  History and mechanism for treatment of intracerebral hemorrhage with scalp acupuncture.

Authors:  Zhe Liu; Ling Guan; Yan Wang; Cheng-Long Xie; Xian-Ming Lin; Guo-Qing Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-22       Impact factor: 2.629

Review 8.  Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact.

Authors:  Frank Gieseler; Hendrik Ungefroren; Utz Settmacher; Morley D Hollenberg; Roland Kaufmann
Journal:  Cell Commun Signal       Date:  2013-11-11       Impact factor: 5.712

9.  Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy.

Authors:  Alex E Roher; David H Cribbs; Ronald C Kim; Chera L Maarouf; Charisse M Whiteside; Tyler A Kokjohn; Ian D Daugs; Elizabeth Head; Carolyn Liebsack; Geidy Serrano; Christine Belden; Marwan N Sabbagh; Thomas G Beach
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

10.  Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.

Authors:  Peng Jin; Shuixiang Deng; Prativa Sherchan; Yuhui Cui; Lei Huang; Gaigai Li; Lifei Lian; Shucai Xie; Cameron Lenahan; Zachary D Travis; John H Zhang; Ye Gong; Jiping Tang
Journal:  Neurotherapeutics       Date:  2021-07-09       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.